Carmen Merali

Suggest Changes
Learn More
602 Background: Although hypertension (HTN) develops in 20-30% of bevacizumab (B)-treated cancer patients, no accurate clinical predictors of B-mediated HTN have been identified. We evaluated(More)
  • 1